Cargando…

Supercritical Fluid Technology for the Development of 3D Printed Controlled Drug Release Dosage Forms

Supercritical CO(2) loading of preformed 3D printed drug carriers with active pharmaceutical ingredients (APIs) shows great potential in the development of oral dosage forms for future personalized medicine. We designed 3D printed scaffold like drug carriers with varying pore sizes made from polylac...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmid, Johannes, Wahl, Martin A., Daniels, Rolf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069480/
https://www.ncbi.nlm.nih.gov/pubmed/33924592
http://dx.doi.org/10.3390/pharmaceutics13040543
_version_ 1783683246734704640
author Schmid, Johannes
Wahl, Martin A.
Daniels, Rolf
author_facet Schmid, Johannes
Wahl, Martin A.
Daniels, Rolf
author_sort Schmid, Johannes
collection PubMed
description Supercritical CO(2) loading of preformed 3D printed drug carriers with active pharmaceutical ingredients (APIs) shows great potential in the development of oral dosage forms for future personalized medicine. We designed 3D printed scaffold like drug carriers with varying pore sizes made from polylactic acid (PLA) using a fused deposition modelling (FDM) 3D printer. The 3D printed drug carriers were then loaded with Ibuprofen as a model drug, employing the controlled particle deposition (CPD) process from supercritical CO(2). Carriers with varying pore sizes (0.027–0.125 mm) were constructed and loaded with Ibuprofen to yield drug-loaded carriers with a total amount of 0.83–2.67 mg API (0.32–1.41% w/w). Dissolution studies of the carriers show a significantly decreasing dissolution rate with decreasing pore sizes with a mean dissolution time (MDT) of 8.7 min for the largest pore size and 128.2 min for the smallest pore size. The API dissolution mechanism from the carriers was determined to be Fickian diffusion from the non-soluble, non-swelling carriers. Using 3D printing in combination with the CPD process, we were able to develop dosage forms with individually tailored controlled drug release. The dissolution rate of our dosage forms can be easily adjusted to the individual needs by modifying the pore sizes of the 3D printed carriers.
format Online
Article
Text
id pubmed-8069480
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80694802021-04-26 Supercritical Fluid Technology for the Development of 3D Printed Controlled Drug Release Dosage Forms Schmid, Johannes Wahl, Martin A. Daniels, Rolf Pharmaceutics Article Supercritical CO(2) loading of preformed 3D printed drug carriers with active pharmaceutical ingredients (APIs) shows great potential in the development of oral dosage forms for future personalized medicine. We designed 3D printed scaffold like drug carriers with varying pore sizes made from polylactic acid (PLA) using a fused deposition modelling (FDM) 3D printer. The 3D printed drug carriers were then loaded with Ibuprofen as a model drug, employing the controlled particle deposition (CPD) process from supercritical CO(2). Carriers with varying pore sizes (0.027–0.125 mm) were constructed and loaded with Ibuprofen to yield drug-loaded carriers with a total amount of 0.83–2.67 mg API (0.32–1.41% w/w). Dissolution studies of the carriers show a significantly decreasing dissolution rate with decreasing pore sizes with a mean dissolution time (MDT) of 8.7 min for the largest pore size and 128.2 min for the smallest pore size. The API dissolution mechanism from the carriers was determined to be Fickian diffusion from the non-soluble, non-swelling carriers. Using 3D printing in combination with the CPD process, we were able to develop dosage forms with individually tailored controlled drug release. The dissolution rate of our dosage forms can be easily adjusted to the individual needs by modifying the pore sizes of the 3D printed carriers. MDPI 2021-04-13 /pmc/articles/PMC8069480/ /pubmed/33924592 http://dx.doi.org/10.3390/pharmaceutics13040543 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Schmid, Johannes
Wahl, Martin A.
Daniels, Rolf
Supercritical Fluid Technology for the Development of 3D Printed Controlled Drug Release Dosage Forms
title Supercritical Fluid Technology for the Development of 3D Printed Controlled Drug Release Dosage Forms
title_full Supercritical Fluid Technology for the Development of 3D Printed Controlled Drug Release Dosage Forms
title_fullStr Supercritical Fluid Technology for the Development of 3D Printed Controlled Drug Release Dosage Forms
title_full_unstemmed Supercritical Fluid Technology for the Development of 3D Printed Controlled Drug Release Dosage Forms
title_short Supercritical Fluid Technology for the Development of 3D Printed Controlled Drug Release Dosage Forms
title_sort supercritical fluid technology for the development of 3d printed controlled drug release dosage forms
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069480/
https://www.ncbi.nlm.nih.gov/pubmed/33924592
http://dx.doi.org/10.3390/pharmaceutics13040543
work_keys_str_mv AT schmidjohannes supercriticalfluidtechnologyforthedevelopmentof3dprintedcontrolleddrugreleasedosageforms
AT wahlmartina supercriticalfluidtechnologyforthedevelopmentof3dprintedcontrolleddrugreleasedosageforms
AT danielsrolf supercriticalfluidtechnologyforthedevelopmentof3dprintedcontrolleddrugreleasedosageforms